Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Several studies have examined the link between the cannabinoid CB1 receptor and several neuropsychiatric illnesses, including schizophrenia. As such, there is a need for in vivo imaging tracers so that the relationship between CB1 and schizophrenia (SZ) can be further studied. In this paper, we present our first human studies in both healthy control patients and patients with schizophrenia using the novel PET tracer, [11C]OMAR (JHU 75528), we have shown its utility as a tracer for imaging human CB1 receptors and to investigate normal aging and the differences in the cannabinoid system of healthy controls versus patients with schizophrenia. A total of ten healthy controls and nine patients with schizophrenia were included and studied with high specific activity [11C]OMAR. The CB1 binding (expressed as the distribution volume; VT) was highest in the globus pallidus and the cortex in both controls and patients with schizophrenia. Controls showed a correlation with the known distribution of CB1 and decline of [11C]OMAR binding with age, most significantly in the globus pallidus. Overall, we observed elevated mean binding in patients with schizophrenia across all regions studied, and this increase was statistically significant in the pons (p<0.05), by the students t-test. When we ran a regression of the control subjects VT values with age and then compared the patient data to 95% prediction limits of the linear regression, three patients fell completely outside for the globus pallidus, and in all other regions there were at least 1-3 patients outside of the prediction intervals. There was no statistically significant correlations between PET measures and the individual Brief Psychiatry Rating Score (BPRS) subscores, but there was a significant correlation between VT and the ratio of the BPRS psychosis to withdrawal score in the frontal lobe (r=0.49), (r=0.60), and middle and posterior cingulate regions (r=0.71 and r=0.79 respectively). In conclusion, we found that [11C] OMAR can image human CB1 receptors in normal aging and schizophrenia. In additon, our initial data in subjects with schizophrenia seem to suggest an association of elevated binding specific brain regions and symptoms of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319
Cognitive and emotional influences in anterior cingulate cortex
Bush, G., Luu, P., & Posner, M. I. (2000) · Trends in Cognitive Sciences · doi:10.1016/s1364-6613(00)01483-2 · Cited by 6,259 · cited 1×
“The Ushaped anterior cingulate VOI was further divided into dorsal, rostral, and sub-callosal subdivisions by a coronal plane that passed through the anterior tip of corpus callosum (Plane C) (Bush et al., 2000; Fornito et al., 2006, 2008; Vogt et al., 2003; Vogt and Laureys, 2005).”
MethodInternational Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321 · cited 1×
“It is noteworthy that the previous autoradiography study with cannabinoid agonist [ 3 H]CP55,940 (Glass et al., 1997; Herkenham et al., 1990) demonstrated the highest binding in the hippocampus and frontal cortex and intermediate binding in the globus pallidus and putamen, whereas [ 11 C]OMAR…”
ResultConsensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Self-citationCannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.
Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002) · BMJ · doi:10.1136/bmj.325.7374.1212 · Cited by 1,399
Glass, M., Faull, R. L. M., & Dragunow, M. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00428-9 · Cited by 1,052 · cited 7×
“Experiments with rats that were chronically treated with various antipsychotic drugs demonstrated (Sundram et al., 2005) that clozapine decreases CB1 binding ([ 3 H]CP55,940) in the nucleus accumbens while other regions (cortex, hippocampus and striatum) showed no change.”
MethodResultInfluentialZammit, S., Allebeck, P., Andreasson, S., Lundberg, I., & Lewis, G. (2002) · BMJ · doi:10.1136/bmj.325.7374.1199 · Cited by 871 · cited 1×
“Multiple lines of evidence show that cannabis and CB1 receptors play a role in psychotic illness and particularly in SZ (Andreasson et al., 1987; Arseneault et al., 2002; Chavarria-Siles et al., 2008; D'Souza, 2007; D'Souza et al., 2005, 2009; Giuffrida et al., 2004; Henquet et al., 2005; Leweke et al., 1999; Ujike et…”
BackgroundDickinson, D., Ramsey, M. E., & Gold, J. M. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.5.532 · Cited by 863 · cited 2×
“Wewould suggest that future studies should consider utilizing matching criteria that include racial group and educational level (Dickinson et al., 2007; Resnick, 1992) in larger samples.”
BackgroundD’Souza, D. C., Abi-Saab, W. M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., Gueorguieva, R., Cooper, T. B., & Krystal, J. H. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.006 · Cited by 617
Cited by
The role of the posterior cingulate cortex in cognition and disease
Leech, R., & Sharp, D. J. (2014) · Brain · doi:10.1093/brain/awt162 · Cited by 2,247
“, 2006), and in vivo PET neuroimaging of the cannabinoid receptor CB1 show that levels in patients correlate with the likelihood of psychotic symptoms (Wong et al., 2010).”
BackgroundEffects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review
Volkow, N. D., Swanson, J. M., Evins, A. E., DeLisi, L. E., Meier, M. H., Gonzalez, R., Bloomfield, M. A. P., Curran, H. V., & Baler, R. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.3278 · Cited by 867
Cannabis and adolescent brain development.
Lubman, D. I., Cheetham, A., & Yücel, M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.009 · Cited by 360
Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors
Benedetti, F., Amanzio, M., Rosato, R., & Blanchard, C. (2011) · Nature Medicine · doi:10.1038/nm.2435 · Cited by 289
A systematic review of the antipsychotic properties of cannabidiol in humans
Iseger, T. A., & Bossong, M. G. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.033 · Cited by 261
Metadata
- Authors
- Wong, D. F., Kuwabara, H., Horti, A. G., Raymont, V., Brasic, J., Guevara, M., Ye, W., Dannals, R. F., Ravert, H. T., Nandi, A., Rahmim, A., Ming, J. E., Grachev, I., Roy, C., & Cascella, N.
- Venue
- NeuroImage
- Publisher
- Elsevier BV
- Published
- 2010-10
- Volume
- 52
- Issue
- 4
- Pages
- 1505-1513
- ISSN
- 1053-8119 (ISSN-L)
- OpenAlex
- W2138566108
- Cited by
- 202
- References
- 13
- FWCI
- 8.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. https://app.cochat.ai/papers/10.1016/j.neuroimage.2010.04.034
- The paper
- Wong, D. F., Kuwabara, H., Horti, A. G., Raymont, V., Brasic, J., Guevara, M., Ye, W., Dannals, R. F., Ravert, H. T., Nandi, A., Rahmim, A., Ming, J. E., Grachev, I., Roy, C., & Cascella, N. (2010). Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. NeuroImage. https://doi.org/10.1016/j.neuroimage.2010.04.034
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.